COVERAGE
February 8, 2023
Read time: 2 min
Kate McDonald, Charles Buck, Sarah Kitchell and Jeremy Earl are featured in Law360 for representing CVS Health.
COVERAGE
February 8, 2023
Read time: 2 min
Kate McDonald, Charles Buck, Sarah Kitchell and Jeremy Earl are featured in Bloomberg Law for representing CVS Health.
COVERAGE
February 8, 2023
Read time: 2 min
Michael Huttenlocher is quoted in Law360 for representing RAM entities. Ethan Townsend, Kevin Regan and Jonathan Kim are also featured in this article for their representation of RAM Entities.
COVERAGE
February 8, 2023
Read time: 2 min
McDermott is featured in Global Legal Chronicle for representing Solaris Health Holdings.
The McDermott deal was led by Joel Rush, Michael Hacker and Joseph Parise and included Nick Alarif, Sarah Bro, Alexander Clavero, Ashley Fischer, Greg Fosheim, Karen Gibbs, Kevin Hall, Sarah Kitchell, Tony Maida, Brian Mead, Caroline Reignley, Alex Ruiz, Chelsea Rutherford, Steven Schnelle, Robert Unger, Allison Wilkerson, Ty Carson, Deepali Doddi, Matthew Chen, Marchan Clark, Josh Cohrs, Daniel Fernandez, Ian Sebastian Gall, Andrew Granek, Jordan Greene, Kyle Hafkey, Liz Hattrup, Abby Higgins, Elaine Kao, Niya Mack, Alison Mackenzie, Marika Miller, Lexi Riccolo, Jon Salm, Danielle Scheer and Jenna Young.
DEAL ANNOUNCEMENT / PRESS RELEASE
February 8, 2023
Read time: 3 min
International law firm McDermott Will & Emery represented Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease, Parkinson’s-related disorders and other diseases, in its $10 million registered direct offering and concurrent private placements. The registered direct offering was for the issuance and sale of 6,744,187 shares of common stock (or common stock equivalents) at a purchase price of $0.86 per share to an institutional investor.
Inhibikase also closed its concurrent private placement for the issuance and sale of 4,883,721 unregistered common stock equivalents at the same purchase price as in the registered direct offering. In addition, and in connection with the offerings, Inhibikase issued unregistered warrants to purchase up to an aggregate of 11,627,908 shares of common stock. The registered direct offering and the private placements were priced at a premium to market under Nasdaq rules.
The transaction was announced on January 25, 2023 and closed on January 27, 2023.
The McDermott deal team was led by Merrill Kraines and Todd Kornfeld and included Brian Malkin, Kishan Mistry, Mike Blane and Mike Kim.
Read Inhibikase’s press release here.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
COVERAGE
February 8, 2023
Read time: 2 min
Nick Alarif and Jerry Sokol are featured in Global Legal Chronicle after the announcement that Nick has rejoined McDermott.
COVERAGE
February 7, 2023
Read time: 2 min
Darren Azman, Joseph Evans, Charles Gibbs, Grayson Williams and Gregg Steinman are featured in Law360 for representing Voyager’s unsecured creditors committee.
COVERAGE
February 7, 2023
Read time: 2 min
Simon Roberts is featured in Bloomberg Law for representing Astellas.
COVERAGE
February 7, 2023
Read time: 2 min
Caroline Reignley, Deborah Godes, Michael Ryan, Dale Van Demark and Marshall Jackson author this article in Law360 which explores potential changes happening to remote monitoring services.
COVERAGE
February 6, 2023
Read time: 2 min
David Hurst, David Giattino, Darren Azman, Michael Huttenlocher, Felicia Perlman, Bradley Giordano and Emily Keil are featured in Law360 for representing PhaseBio’s official committee of unsecured creditors.
